|
|
|
| Investigate of the mechanism of the influence of myeloid-derived suppressor cells on chronic colitis associated carcinogenesis through immunometabolic pathways |
| HE Shanquan1 CHEN Xue1 LI Weidong2 |
1.Department of Oncology Guang’an men Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China;
2.Department of Scientific Research Management, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China |
|
|
|
Abstract Myeloid-derived suppressor cells (MDSC) form an immunosuppressive microenvironment that affects the progression of chronic colitis associated carcinogenesis (CAC). In the inflammatory state, abnormal mitochondrial metabolism and hypoxia participate in the regulation of MDSC and affect the progression of CAC. Adenosine 5’-monophosphate- activated protein kinase (AMPK) activation inhibits hypoxia inducible factor-1αregulation of MDSC. This article intends to explore how MDSC regulates and affects the carcinogenesis of chronic colitis from the pathway of inflammatory immune metabolism, in order to provide clues and evidence for the prevention and treatment of colorectal cancer.
|
|
|
|
|
|
[1] Fernández-Montes A，Grávalos C，Pericay C，et al. Current Options for Third-line and Beyond Treatment of Metastatic Colorectal Cancer. Spanish TTD Group Expert Opinion [J]. Clin Colorectal Cancer，2020，19（3）：165-177.
[2] Seril DN，Liao J，Yang GY，et al. Oxidative stress and ulcerative colitis-associated carcinogenesis：studies in humans and animal models [J]. Carcinogenesis，2003，24（3）：353- 362.
[3] Rutter M，Saunders B，Wilkinson K，et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis [J]. Gastroenterology，2004，126（2）：451-459.
[4] Fantini MC，Pallone F. Cytokines：from gut inflammation to colorectal cancer [J]. Curr Drug Targets，2008，9（5）：375- 380.
[5] Sada O，Ahmed K，Jeldo A，et al. Role of Anti-inflammatory Drugs in the Colorectal Cancer [J]. Hosp Pharm，2020，55（3）：168-180.
[6] Grivennikov S，Karin E，Terzic J，et al. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer [J]. Cancer Cell，2009， 15（2）：103-113.
[7] Eaden J. Review article：the data supporting a role for aminosalicylates in the chemoprevention of colorectal cancer in patients with inflammatory bowel disease [J]. Aliment Pharmacol Ther，2003，18 Suppl 2：15-21.
[8] Greten FR，Grivennikov SI. Inflammation and Cancer：Triggers，Mechanisms，and Consequences [J]. Immunity，2019，51（1）：27-41.
[9] Wu T，Dai Y. Tumor microenvironment and therapeutic response [J]. Cancer Lett，2017，387：61-68.
[10] Anderson NM，Simon MC. The tumor microenvironment [J]. Curr Biol，2020，30（16）：R921-R925.
[11] Segal A W. Studies on patients establish Crohn’s disease as a manifestation of impaired innate immunity [J]. J Intern Med，2019，286（4）：373-388.
[12] Waldner MJ，Neurath MF. Colitis-associated cancer：the role of T cells in tumor development [J]. Semin Immunopathol，2009，31（2）：249-256.
[13] Ortiz ML，Kumar V，Martner A，et al. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells [J]. J Exp Med，2015，212（3）：351-367.
[14] Ostrand-Rosenberg S，Sinha P. Myeloid-derived suppressor cells：linking inflammation and cancer [J]. J Immunol，2009，182（8）：4499-4506.
[15] Kumar V，Patel S，Tcyganov E，et al. The Nature of Myeloid- Derived Suppressor Cells in the Tumor Microenvironment [J]. Trends Immunol，2016，37（3）：208-220.
[16] Wang Y，Ding Y，Deng Y，et al. Role of myeloid-derived suppressor cells in the promotion and immunotherapy of colitis-associated cancer [J]. J Immunother Cancer，2020，8（2）：e000609.
[17] Liu C，Yu S，Kappes J，et al. Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host [J]. Blood，2007，109（10）：4336-4342.
[18] Zhang H，Li ZL，Ye SB，et al. Myeloid-derived suppressor cells inhibit T cell proliferation in human extranodal NK/T cell lymphoma：a novel prognostic indicator [J]. Cancer Immunol Immunother，2015，64（12）：1587-1599.
[19] Gabrilovich DI，Ostrand-Rosenberg S，Bronte V. Coordinated regulation of myeloid cells by tumours [J]. Nat Rev Immunol，2012，12（4）：253-268.
[20] Serafini P，Mgebroff S，Noonan K，et al. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells [J]. Cancer Res，2008，68（13）：5439-5449.
[21] Dubeykovskaya Z，Si Y，Chen X，et al. Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer [J]. Nat Commun，2016，7，10517.
[22] Kontaki E，Boumpas DT，Tzardi M，et al. Aberrant function of myeloid-derived suppressor cells （MDSCs） in experimental colitis and in inflammatory bowel disease （IBD） immune responses [J]. Autoimmunity，2017，50（3）：170- 181.
[23] Neut C，Bulois P，Desreumaux P，et al. Changes in the bacterial flora of the neoterminal ileum after ileocolonic resection for Crohn's disease [J]. Am J Gastroenterol，2002，97（4）：939-946.
[24] Corzo CA，Cotter MJ，Cheng P，et al. Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells [J]. J Immunol，2009，182（9）：5693-5701.
[25] de Barrios O，Sanchez-Moral L，Cortés M，et al. ZEB1 promotes inflammation and progression towards inflammation-driven carcinoma through repression of the DNA repair glycosylase MPG in epithelial cells [J]. Gut，2019，68（12）：2129-2141.
[26] Ma P，Beatty PL，Mckolanis J，et al. Circulating Myeloid Derived Suppressor Cells （MDSC） That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer [J]. Front Immunol，2019，10：1401.
[27] Condamine T，Ramachandran I，Youn JI，et al. Regulation of tumor metastasis by myeloid-derived suppressor cells [J]. Annu Rev Med，2015，66：97-110.
[28] Chun E，Lavoie S，Michaud M，et al. CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function [J]. Cell Rep，2015，12（2）：244-257.
[29] Ma N，Liu Q，Hou L，et al. MDSCs are involved in the protumorigenic potentials of GM-CSF in colitis-associated cancer [J]. Int J Immunopathol Pharmacol，2017，30（2）：152-162.
[30] Ip WKE，Hoshi N，Shouval DS，et al. Anti-inflammatory effect of IL-10 mediated by metabolic reprogramming of macrophages [J]. Science，2017，356（6337）：513-519.
[31] Ganeshan K，Chawla A. Metabolic regulation of immune responses [J]. Annu Rev Immunol，2014，32：609-634.
[32] Pearce EL，Walsh MC，Cejas PJ，et al. Enhancing CD8 T-cell memory by modulating fatty acid metabolism [J]. Naturre，2009，460（7251）：103-107.
[33] Smolková K，Plecitá-Hlavatá L，Bellance N，et al. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells [J]. Int J Biochem Cell Biol，2011，43（7）：950-968.
[34] Baker KT，Nachmanson D，Kumar S，et al. Mitochondrial DNA Mutations are Associated with Ulcerative Colitis Preneoplasia but Tend to be Negatively Selected in Cancer [J]. Mol Cancer Res，2019，17（2）：488-498.
[35] Han J，Jackson D，Holm J，et al. Elevated d-2-hydroxyglutarate during colitis drives progression to colorectal cancer [J]. Proc Natl Acad Sci U S A，2018，115（5）：1057-1062.
[36] Zhu YP，Brown JR，Sag D，et al. Adenosine 5’-monophosphate-activated protein kinase regulates IL-10-mediated anti-inflammatory signaling pathways in macrophages [J]. J Immunol，2015，194（2）：584-594.
[37] Carroll KC，Viollet B，Suttles J. AMPKα1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling [J]. J Leukoc Biol，2013，94（6）：1113-1121.
[38] Dandapani M，Hardie DG. AMPK：opposing the metabolic changes in both tumour cells and inflammatory cells? [J]. Biochem Soc Trans，2013，41（2）：687-693.
[39] Petti C，Vegetti C，Molla A，et al. AMPK activators inhibit the proliferation of human melanomas bearing the activated MAPK pathway [J]. Melanoma Res，2012，22（5）：341-350.
[40] Noman MZ，Desantis G，Janji B，et al. PD-L1 is a novel direct target of HIF-1α，and its blockade under hypoxia enhanced MDSC-mediated T cell activation [J]. J Exp Med，2014，211（5）：781-790.
[41] Shi G，Li D，Zhang D，et al. IRF-8/miR-451a regulates M-MDSC differentiation via the AMPK/mTOR signal pathway during lupus development [J]. Cell Death Discov，2021， 7（1）：179. |
|
|
|
